Population pharmacokinetics in geriatric psychiatry

American Journal of Geriatric Psychiatry

Volumn 14, Issue 12, 2006, Pages 993-1003

  Bigos, Kristin L ^a   Bies, Robert R ^a   Pollock, Bruce G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Modeling; Pharmacokinetics; Population

Indexed keywords

ALPRAZOLAM; ANTIRETROVIRUS AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CEFOTAXIME; CITALOPRAM; CLOZAPINE; DEACETYLCEFOTAXIME; DIDANOSINE; EFAVIRENZ; ESCITALOPRAM; FLUPHENAZINE; IMIPRAMINE; LITHIUM; NEUROLEPTIC AGENT; NEVIRAPINE; NIFEDIPINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VERAPAMIL; ZIDOVUDINE; ZIPRASIDONE;

AGED; BIPOLAR DISORDER; CONTINUOUS INFUSION; DEPRESSION; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; EPILEPSY; GERONTOPSYCHIATRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; MODEL; OUTCOME ASSESSMENT; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA;

EID: 33845581407     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.JGP.0000224330.73063.6c     Document Type: Article

References (49)

1. Mulsant BH, Pollock BG, Kirshner M, et al: Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry 2003; 60:198-203
2. Turnheim K: When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38:843-853
3. Turnheim K: Drug therapy in the elderly. Exp Gerontol 2004; 39:1731-1738
4. Gurwitz JH, Field TS, Harrold LR, et al: Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2005; 289:1107-1116
5. Mannesse CK, Derkx FHM, deRidder MAJ, et al: Adverse drug reactions in elderly patients as contributing factor for hospital admission: cross sectional study. BMJ 1997; 315:1057-1058
6. ICH Expert Working Group: ICH Harmonised Tripartite Guideline: dose-response information to support drug registration (E4). Paper presented at the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1994
7. ICH Expert Working Group: ICH Harmonised Tripartite Guideline: Studies in support of special populations: geriatrics (E7). Paper presented at the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1993
8. Sheiner LB, Steimer J-L: Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40:67-95
9. Ette EI, Williams PJ: Population pharmacokinetics II: Estimation methods. Ann Pharmacother 2004; 38:1907-1915
10. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8:553-571
11. Schoemaker R: Modelling Repeated Measurements in Clinical Pharmacology; from Individual to Population and Back [PhD thesis]. Leiden, The Netherlands: Centre for Human Drug Research, Leiden University, 1999
12. Ette EI, Williams PJ: Population pharmacokinetics I: Background, concepts, and models. Ann Pharmacother 2004; 38:1702-1706
13. Davidian M, Giltinan DM: Nonlinear Models for Repeated Measurement Data. Boca Raton, FL, Chapman & Hall/CRC, 1995
14. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten Model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1980; 8:553-571
15. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 1981; 9:635-651
16. Sheiner LB, Beal SL: Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11:303-319
17. Sheiner LB, Beal SL: Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci 1982; 71:1344-1348
18. Sheiner LB: The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev 1984; 15:153-171
19. Callaghan JT, Bergstrom RF, Ptak LR, et al: Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37:177-193
20. Krecic-Shepard ME, Park K, Barnas C, et al: Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68:130-142
21. Kang D, Verotta D, Krecic-Shepard ME, et al: Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther 2003; 73:31-40
22. Urien S, Laurent N, Barre J, et al: Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime - a population study in 25 elderly patients. Eur J Pharmacol 2004; 60:11-16
23. Zhou X-J, Sheiner LB, D'Aquila RT, et al: Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1999; 43:121-128
24. Vozeh S, Muir KT, Sheiner LB, et al: Predicting individual phenytoin dosage. J Pharmacokinet Biopharm 1981; 9:131-146
25. Sheiner LB, Grasela TH: Experience with NONMEM: analysis of routine phenytoin clinical pharmacokinetic data. Drug Metab Rev 1984; 15:293-303
26. Killilea T, Coleman R, Ludden T, et al: Bayesian regression analysis of non-steady-state phenytoin concentrations: evaluation of predictive performance. Ther Drug Monit 1989; 11:455-462
27. Privitera MD, Homan RW, Ludden TM, et al: Clinical utility of a Bayesian dosing program for phenytoin. Ther Drug Monit 1989; 11:285-294
28. Godley PJ: Evaluation of a Bayesian regression-analysis computer program using non-steady-state phenytoin concentrations. Clinical Pharmacy 1987; 6:634-639
29. Brundage RC, Yong FH, Fenton T, et al: Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 2004; 48:979-984
30. Pollock BG: The pharmacokinetic imperative in late-life depression. J Clin Psychopharmacol 2005; 25:S19-S23
31. Bies RR, Feng Y, Lotrich FE, et al: Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol 2004; 44:1352-1359
32. Kupfer DJ, Gelenberg AJ, Goldberg JF, et al: Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry 2001; 62:985-990
33. Roose SP, Sackeim HA, Krishnan KRR, et al: Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004; 161:2050-2059
34. Reynolds CF III, Dew MA, Pollock BG, et al: Maintenance treatment of major depression in old age. N Engl J Med 2006; 354:1130-1138
35. Feng Y, Pollock BG, Ferrell RE, et al: Paroxetine: population pharmacokinetics analysis in late-life depression using sparse concentration sampling. Brit J Clin Pharmacol 2006; 61:558-569
36. DeVane CL, Grasela Jr, TH Antal EJ, et al: Evaluation of population pharmacokinetics in therapeutic trials. IV. Application to postmarketing surveillance. Clin Pharmacol Ther 1993; 53:521-528
37. Gaillot J, Steimer J-LJ, Mallet AJ, et al: A priori lithium dosage regimen using population characteristic of pharmacokinetic parameters. J Pharmacokinet Biopharm 1979; 7:579-628
38. Jermain DM, Crismon ML, Martin ES: Population pharmacokinetics of lithium. Clinical Pharmacy 1991; 10:376-381
39. Yukawa E, Nomiyama N, Higuchi S, et al: Lithium population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens. Ther Drug Monit 1993; 15:75-82
40. Kimko HC, Reele SSB, Holford NHG, et al: Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 68:568-577
41. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
42. Bigos KL, Pollock BG, Coley KC, et al: Sources of variability in olanzapine exposure from the CATIE-AD study [Abstract]. Society of Biological Psychiatry 2006
43. Chew ML, Pollock BG, Coley KC, et al: Population pharmacokinetic model of quetiapine using highly sparse data from the CATIE study [Abstract]. Society of Biological Psychiatry 2006.
44. Feng Y, Pollock BG, Coley KC, et al: Assessing sources of variability in risperidone pharmacokinetics: a population analysis of risperidone using highly sparse sampling measurements from the CATIE study [Abstract]. Society of Biological Psychiatry 2006
45. Grasela Jr, TH Antal EJ, Ereshefsky L, et al: An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther 1987; 42:433-441
46. Bies RR, Mulsant BH, Rosen J, et al: Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. Am J Geriatr Pharmacother 2005; 3:1-5
47. Bies RR, Gastonguay MR, Coley KC, et al: Evaluating the consistency of pharmacotherapy exposure by use of state-of-the-art techniques. Am J Geriatr Psychiatry 2002; 10:696-705
48. Holford N, Hale M, Ko H, et al: Simulation in drug development: good practices. In: Center for Drug Development Science. Modeling & Simulation of Clinical Trials: Best Practices Workshop. Arlington, VA, Georgetown University Medical Center, 1999
49. Holford NHG, Kimko HC, Monteleone JPR, et al: Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40:209-234